Glaxosmithkline Pharmaceuticals Limited · NSE:GLAXO
Glaxosmithkline Pharmaceuticals — Q1 FY25 Earnings Presentation
12 slides from Glaxosmithkline Pharmaceuticals's earnings presentation, Aug 5, 2024
Slide 1: Outcome of Schedule of Analyst / Institutional Investor Meetings
GlaxoSmithKline Pharmaceuticals Limited GSK House, Dr. Annie Besant Road, Worli, Mumbai - 400 030 Tel No: +91 22 2495 9595 Fax No: +91 22 2495 9494 Web: www.gsk-india.com Email: askus@gsk.com 5th August 2024 To, BSE LIMITED THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Phiroze Jeejeebhoy Towers Excha
Slide 2: Slide 2
Slide 3: Bhushan Akshikar, Managing Director; Juby Chandy, Chief Financial Officer
Bhushan Akshikar, Managing Director Mr. Bhushan Akshikar has an experience of over 14 years in key leadership roles in GSK across India, Middle East, Russia CIS & Africa region. Before joining GSK, Bhushan spent 15 years with Johnson & Johnson, in local and regional positions in India, S. Korea and
Slide 4: GSK India's commercial ambition is driven by focus, innovation and agility
GSK India’s commercial ambition is driven by focus, innovation and agility, underpinned by continuous cultural transformation Innovate to be competitive Our Portfolio Pioneering new ideas and solutions to increase access and provide differentiated customer experience General Medicines & Specialty An
Slide 5: General Medicines and Pediatric Vaccines deliver competitive external performance in Q1
General Medicines and Pediatric Vaccines deliver competitive external performance in Q1 General Medicines growing at par with market Improving our SoV for General Medicines 100 Unit EI Brand Value EI Augmentin 101 Calpol OS 100 Ceftum 91* (Unit EI 131) T-Bact 100 Trelegy 109 Elevating customer exper
Slide 6: Slide 6
Slide 7: Shingrix update across 'must wins'
Shingrix update across ‘must wins’ Creating an adult vaccination ecosystem to address needs of 12Mn target addressable market Win with HCPs Educate Consumers Create channels Create Vaccinators Drive Awareness Develop Vaccination Ecosystem Partnerships to create adult Drive awareness and Partnership
Slide 8: Continuing the social conversations with topical posts on Shingles
Continuing the social conversations with topical posts on Shingles 05 August 2024 7
Slide 9: Apr-Jun'24 (Q1 FY25): Financial Highlights
Apr-Jun’24 (Q1 FY25): Financial Highlights Revenue EBITDA PAT ₹811cr ₹229cr ₹182cr Growth +10% Growth +62% Growth+39% Margin: 28% Margin: 23% Strong double-digit growth EBITDA margin +920 bps (YoY) PAT +480 bps (YoY) ▪ EBITDA margin growing consistently (+12% ▪ GSK growth +10% vs India pharma market
Slide 10: EBITDA margins improves consistently
EBITDA margins improves consistently 400 28.4% 30.1% 28.0% 28.3% + ~920 bps EBITDA margin (YoY) 28.5% 27.0% 350 300 20.3% 21.3% 287 19.1% 257 255 250 230 228 218 200 148 167 Focus on Efficiency 141 150 Improvement in Field productivity ; HC optimization 100 Digital Acceleration : Leveraging omnichan
Slide 11: GSK India Ambition
GSK India Ambition Deliver double digit growth to touch the lives of a billion Indians Deliver exceptional new launches for driving innovation growth led by Shingrix Continue competitive performance with profitable growth in the base business Evolve a culture where our people #AheadTogether develop,
Slide 12: gsk.com
gsk.com
GlaxoSmithKline Pharmaceuticals — Q1 FY25 Earnings Presentation on 6ix